Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 42.48B | 31.98B | 23.07B | 15.33B | 9.17B |
Gross Profit | 17.06B | 13.27B | 9.69B | 6.30B | 3.75B |
EBITDA | 12.76B | 10.39B | 7.10B | 4.48B | 2.17B |
Net Income | 7.44B | 6.31B | 4.28B | 2.63B | 1.24B |
Balance Sheet | |||||
Total Assets | 71.80B | 55.56B | 41.77B | 31.92B | 16.52B |
Cash, Cash Equivalents and Short-Term Investments | 8.87B | 12.13B | 11.34B | 11.19B | 3.33B |
Total Debt | 31.75B | 23.05B | 17.43B | 12.75B | 9.55B |
Total Liabilities | 38.59B | 29.04B | 21.31B | 15.58B | 11.27B |
Stockholders Equity | 33.21B | 26.52B | 20.46B | 16.34B | 5.25B |
Cash Flow | |||||
Free Cash Flow | -8.52B | -3.06B | -2.73B | -2.79B | -3.78B |
Operating Cash Flow | 7.48B | 6.80B | 4.42B | 2.58B | 1.17B |
Investing Cash Flow | -16.83B | -10.31B | -7.75B | -5.78B | -5.30B |
Financing Cash Flow | 6.08B | 4.30B | 3.49B | 11.05B | 7.02B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | ¥59.97B | 9.42 | 0.66% | 26.79% | -9.91% | ||
51 Neutral | $7.95B | -0.38 | -42.44% | 2.22% | 22.30% | -1.83% | |
― | €283.67M | 18.36 | 20.78% | ― | ― | ― | |
78 Outperform | ¥20.10B | 11.48 | 3.65% | 4.31% | -9.01% | ||
74 Outperform | ¥46.14B | 10.56 | 4.11% | 1.43% | ― | ||
66 Neutral | ¥33.77B | 14.23 | ― | 37.50% | -22.93% | ||
58 Neutral | ¥33.68B | 11.49 | 3.29% | -2.42% | -31.36% |
Amvis Holdings, Inc. has announced a series of improvement measures following an investigation into its operations, prompted by media reports of potential improper medical fee claims. The investigation found no organizational misconduct but highlighted areas needing improvement. In response, Amvis is implementing measures to define and standardize home-visit nursing services, enhance recruitment and staffing systems, rebuild internal controls, and improve internal communication. These initiatives aim to strengthen the company’s operational efficiency and compliance, ultimately benefiting stakeholders by ensuring accurate service delivery and robust internal processes.
Amvis Holdings, Inc. has announced the completion of its semi-annual report submission for the fiscal year ending September 30, 2025, following an approved extension. The company expressed apologies for any inconvenience caused by the delay, emphasizing its commitment to maintaining transparency and accountability with its stakeholders.
Amvis Holdings, Inc. announced a delay in the disclosure of its financial results for the third quarter of the fiscal year ending September 30, 2025. The delay, expected to exceed 45 days post-quarter, is due to the time required to complete procedures related to the financial results. This postponement may cause inconvenience and concern among stakeholders, but the company assures that the specific date for the announcement will be disclosed promptly once determined.
Amvis Holdings, Inc. reported a decline in profits for the first six months of the fiscal year ending September 30, 2025, despite an increase in net sales. The company’s operating profit and profit attributable to owners of the parent decreased significantly compared to the previous year, indicating challenges in maintaining profitability. The company also announced the inclusion of a new subsidiary, Midori, in its consolidated financial statements, reflecting strategic expansion efforts.
Amvis Holdings, Inc. has received an investigation report from a Special Investigation Committee, which was formed to examine allegations of improper billing of medical fees. The investigation found no evidence of systematic misconduct, and the financial impact is minor, amounting to approximately ¥63 million. The company acknowledges deficiencies in its internal systems and is committed to improvements, including organizational restructuring and enhanced recordkeeping. The findings have caused concern among stakeholders, and Amvis plans to disclose further initiatives at its upcoming earnings announcement.